BR112016019534A2 - methods of treating tumor growth and eliciting an enhanced immune response against tumor growth - Google Patents

methods of treating tumor growth and eliciting an enhanced immune response against tumor growth

Info

Publication number
BR112016019534A2
BR112016019534A2 BR112016019534A BR112016019534A BR112016019534A2 BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2 BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2
Authority
BR
Brazil
Prior art keywords
tumor growth
methods
immune response
response against
eliciting
Prior art date
Application number
BR112016019534A
Other languages
Portuguese (pt)
Inventor
Wallecha Anu
Seavey Matthew
MASON Nicola
C Maciag Paulo
Shahabi Vafa
Paterson Yvonne
Original Assignee
Advaxis Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by Advaxis Inc, Univ Pennsylvania filed Critical Advaxis Inc
Publication of BR112016019534A2 publication Critical patent/BR112016019534A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

esta invenção fornece composições e métodos para o tratamento e vacinação contra um tumor que expressa antígeno de her2/neu e indução de uma resposta imune contra o mesmo em um indivíduo.This invention provides compositions and methods for treating and vaccinating a tumor expressing her2 / neu antigen and inducing an immune response against it in an individual.

BR112016019534A 2014-02-25 2015-02-25 methods of treating tumor growth and eliciting an enhanced immune response against tumor growth BR112016019534A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (1)

Publication Number Publication Date
BR112016019534A2 true BR112016019534A2 (en) 2017-10-24

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019534A BR112016019534A2 (en) 2014-02-25 2015-02-25 methods of treating tumor growth and eliciting an enhanced immune response against tumor growth

Country Status (13)

Country Link
EP (1) EP3110942A4 (en)
JP (1) JP2017507943A (en)
KR (2) KR20240038103A (en)
CN (1) CN106661538A (en)
AU (1) AU2015223136A1 (en)
BR (1) BR112016019534A2 (en)
CA (1) CA2940646A1 (en)
IL (1) IL247436A0 (en)
MX (1) MX2016011114A (en)
NZ (1) NZ723750A (en)
RU (1) RU2016137834A (en)
SG (1) SG11201607036XA (en)
WO (1) WO2015130810A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
CN106456726A (en) 2014-02-18 2017-02-22 阿德瓦希斯公司 Biomarker directed multi-target immunotherapy
US20170080064A1 (en) * 2014-03-05 2017-03-23 Advaxis, Ins. Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
TWI765875B (en) 2015-12-16 2022-06-01 美商磨石生物公司 Neoantigen identification, manufacture, and use
KR20190082850A (en) 2016-11-30 2019-07-10 어드박시스, 인크. Immunogen compositions targeting repeated cancer mutations and methods of using the same
NZ762881A (en) 2017-09-19 2024-03-22 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. Neoantigen identification using hotspots
JP2021503897A (en) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド Reduced junction epitope presentation for nascent antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
EP3110942A4 (en) 2017-08-30
WO2015130810A3 (en) 2016-01-28
AU2015223136A1 (en) 2016-09-22
IL247436A0 (en) 2016-11-30
EP3110942A2 (en) 2017-01-04
KR20240038103A (en) 2024-03-22
KR20160122829A (en) 2016-10-24
CN106661538A (en) 2017-05-10
MX2016011114A (en) 2017-02-20
CA2940646A1 (en) 2015-09-03
RU2016137834A (en) 2018-03-29
WO2015130810A2 (en) 2015-09-03
SG11201607036XA (en) 2016-09-29
JP2017507943A (en) 2017-03-23
NZ723750A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
BR112016019534A2 (en) methods of treating tumor growth and eliciting an enhanced immune response against tumor growth
CY1122602T1 (en) TREATMENT OF NAFLD AND NASH
BR112017013176A2 (en) chimeric antigen receptors and methods for using them
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL252159A0 (en) Methods and formulations for treating vascular eye diseases
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
CL2016001871A1 (en) Human antibodies for PD-1
SV2018005659A (en) AGONIST ANTIBODIES THAT SPECIFICALLY JOIN CD40 HUMANS AND METHODS OF USE
IL263382A (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
BR112016026378A2 (en) formulations and methods for keratin treatment
NZ731467A (en) Anti-tim3 antibodies and methods of use
BR112017008959A2 (en) method for treating a disease.
MX2017005258A (en) Combination therapy for treatment of disease.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
BR112019002331A2 (en) anti-siglec-7 antibodies for cancer treatment and methods of obtaining them
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2016015162A (en) Anti-gpc3 antibodies and immunoconjugates.
EP3542742A4 (en) Customized surgical guide and customized surgical guide generating method and generating program
MX2017005975A (en) Anti-pdgf-b antibodies and methods of use.
EA201891478A1 (en) METHODS AND COMPOSITIONS FOR RISK ASSESSMENT FOR CANCER
MA51730A (en) DIMETHYL FUMARATE AND IMMUNIZATION REGIMES
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
UY36286A (en) ANAMORELINE-BASED MEDICAL TREATMENTS
CL2016001906A1 (en) Vaccines against avian reovirus.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]